Saturday 17 October 2026
Export JAGX’s income statement to Excel — free account
Jaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024. In the quarter to June 2026, revenue fell 58.9%, EPS grew 95.6%, free cash flow grew 13.8% and total debt fell 83.9%, each against the same quarter a year earlier.
3.53
1.06
−23.09%
Follow JAGX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | — | 5 | 3 | 5 | 3 | 5 | 5 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.19 | 0.68 | 0.00 | 570,133.93 | 8,447,885.81 | 198,201,062.85 | 122,027,886.88 | 134,870,293.78 | 18,282,754,417.67 | 9,661,624,906,836.67 |
Altman Z-Score |
(18.88) | (10.38) | (9.59) | 82,833.50 | 530,585.90 | 43,526,773.58 | 26,690,222.50 | 13,405,267.72 | 1,716,227,051.95 | 145,461,044,075.35 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(45.89) | (23.34) | (22.42) | (24.35) | (16.67) | (15.47) | (16.95) | (14.95) | (10.99) | (66.06) |
P/Operating CF |
(0.39) | (1.02) | 0.00 | (1,061,267.52) | (4,104,178.53) | (458,044,071.62) | (224,430,269.65) | (121,504,323.01) | (14,958,991,443.11) | (501,290,673,334.33) |
Beneish M-Score |
(6.24) | (3.51) | (3.37) | (3.14) | (4.74) | (3.73) | (4.08) | (2.08) | 34.91 | (5.09) |
P/B ratio |
0.00 | 1.22 | 0.00 | 0.00 | 3,089,646.92 | 108,133,762.05 | 78,642,009.45 | 110,645,202.84 | 4,619,252,667.34 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.96 | 2.14 | 2.68 | 570,135.09 | 8,447,888.02 | 198,201,063.48 | 122,027,886.56 | 134,870,295.98 | 18,282,754,420.39 | 9,661,624,906,852.75 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.46) | (0.85) | (0.79) | (205,912.73) | (1,047,228.90) | (121,751,340.54) | (34,448,406.16) | (26,202,958.15) | (8,115,392,553.89) | (94,848,645,685.68) |
EV/FCF |
(0.45) | (0.80) | (0.72) | (189,543.01) | (1,047,049.25) | (121,695,582.65) | (34,436,622.60) | (26,195,467.41) | (8,030,226,334.99) | (94,167,884,082.39) |
Quick Ratio |
0.23 | 0.49 | 0.62 | 0.26 | 1.24 | 0.96 | 0.36 | 0.13 | 0.08 | 0.35 |
Current Ratio |
0.50 | 1.63 | 2.00 | 0.74 | 1.84 | 1.35 | 0.62 | 0.31 | 0.25 | 0.61 |
Net Debt/EBITDA |
(0.17) | (0.55) | (1.31) | (0.60) | (0.24) | (0.20) | 0.16 | 0.11 | (0.73) | (0.17) |
Debt/Assets |
39.36% | 43.99% | 61.05% | 37.39% | 46.98% | 28.99% | 1.24% | 0.00% | 28.86% | 104.89% |
Debt/Equity |
(0.81) | 3.62 | 6.33 | (13.09) | 2.11 | 0.72 | 0.02 | 0.00 | 0.73 | (1.52) |
Asset Turnover |
0.25 | 0.22 | 0.20 | 0.24 | 0.09 | 0.24 | 0.15 | 0.10 | 0.18 | 0.02 |
Operating CF/Net income |
0.44 | 0.76 | 0.80 | 0.70 | 0.66 | 0.40 | 0.46 | 0.71 | 0.45 | 0.98 |
Capex/Depreciation |
(0.02) | (0.09) | 0.00 | (0.12) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.19) |
Interest Coverage |
(685.19) | (133.47) | (5.37) | (2.70) | (4.83) | (9.54) | (5.05) | (11.73) | (28.31) | (13.79) |
| 729.95% | (675.83%) | (2,332.67%) | (904.14%) | (362.04%) | (295.44%) | (623.62%) | (283.92%) | (296.74%) | (1,515.12%) | |
| (116.79%) | (73.89%) | (84.10%) | (94.23%) | (109.45%) | (97.53%) | (115.49%) | (75.93%) | (93.10%) | (184.54%) | |
ROIC |
0.00% | (87.61%) | (72.85%) | (196.99%) | (128.34%) | (77.34%) | (105.59%) | (163.06%) | (73.57%) | 0.00% |
Return on Tangible Assets |
269.95% | (297.05%) | (285.38%) | 636.03% | (386.36%) | (736.29%) | 866.78% | 181.12% | 211.96% | 1,959.28% |
Average Days of Receivables |
53.84 | 51.43 | 81.67 | 75.31 | 180.52 | 177.35 | 107.07 | 82.80 | 39.25 | 12.90 |
Research and Development Expense of Revenue |
216.89% | 141.52% | 190.51% | 147.60% | 347.84% | 68.33% | 100.78% | 116.73% | 97.90% | 5,093.22% |
Selling, General and Administrative Expense of Revenue |
242.19% | 205.52% | 236.12% | 223.36% | 599.70% | 223.72% | 353.90% | 500.64% | 328.61% | 4,571.52% |
Intangible Assets out of Total Assets |
0.42 | 0.35 | 0.40 | 0.47 | 0.43 | 0.57 | 0.71 | 0.77 | 0.88 | 0.00 |
Share Based Compensation of Revenue |
7.22% | 14.12% | 23.39% | 34.64% | 92.04% | 40.58% | 54.18% | 45.97% | 19.68% | 507.35% |
Graham Net Nets |
(17.05) | (1.85) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
35,872.10 | 0.00 | 0.00 | 29.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.60 |
Earnings Yield |
(2,431.58%) | (532.57%) | (1,195.45%) | 0.00% | (2.00%) | 0.00% | (16.74%) | (21.92%) | 0.00% | 0.00% |
Free Cash Flow Yield |
(1,133.29%) | (392.43%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
2,616.14 | 19,481.67 | 0.00 | 9.12 | 7.27 | 0.73 | 1.16 | 21.06 | 1.51 | 0.01 |
Operating CF per Share |
(5,383.18) | (48,973.33) | 0.00 | (25.24) | (58.65) | (1.19) | (4.12) | (108.40) | (3.39) | (1.32) |
Capex per Share |
(9.32) | (385.00) | 0.00 | (1.28) | (0.01) | 0.00 | 0.00 | (0.03) | 0.00 | (0.01) |
Free Cash Flow per Share |
(5,392.50) | (49,358.33) | 0.00 | (26.52) | (58.66) | (1.19) | (4.12) | (108.43) | (3.39) | (1.33) |
Cash per Share |
1,780.00 | 13,336.67 | 0.00 | 4.17 | 28.60 | 0.63 | 0.78 | 12.25 | 0.26 | 0.13 |
Shareholders Equity per Share |
(4,247.27) | 10,823.33 | 0.00 | (1.03) | 19.88 | 1.34 | 4.14 | 68.59 | 5.96 | (0.22) |
Interest Debt per Share |
0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(4,247.27) | 10,823.33 | 0.00 | (1.03) | 19.88 | 1.34 | 4.14 | 68.59 | 5.96 | (0.22) |
Free Cash Flow |
(23.73) | (29.61) | (33.24) | (34.78) | (34.98) | (15.28) | (20.46) | (22.74) | (9.82) | (14.52) |
Working Capital |
(20.31) | 12.49 | 13.98 | (8.02) | 12.96 | 4.57 | (5.87) | (18.51) | (11.59) | (1.64) |
Capital Expenditures |
(0.04) | (0.23) | 0.00 | (1.67) | (0.01) | (0.01) | — | (0.01) | — | (0.10) |
Net Current Asset Value |
(36.67) | (14.73) | (17.90) | (26.49) | (12.98) | (7.85) | (6.32) | (18.51) | (22.57) | (3.46) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.02 | 0.00 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
5.09 | 5.67 | 31.44 | 25.22 | 10.74 | 7.31 | 9.98 | 10.16 | 14.74 | 0.63 |
Cash ROIC |
(561.32%) | (77.94%) | (78.48%) | (159.12%) | (64.86%) | (40.53%) | (82.15%) | (134.13%) | (32.09%) | (528.83%) |
Accounts Receivable Turnover |
6.88 | 6.10 | 4.20 | 5.19 | 1.29 | 3.00 | 4.28 | 6.01 | 18.40 | 4.65 |
Accounts Payable Turnover |
0.54 | 0.38 | 0.38 | 0.38 | 0.48 | 0.65 | 0.71 | 0.43 | 0.22 | 0.10 |
Inventory Turnover |
0.40 | 0.20 | 0.25 | 0.34 | 0.61 | 1.34 | 1.39 | 1.02 | 0.71 | 0.16 |
Average Days of Payables |
840.06 | 986.90 | 891.27 | 1,049.99 | 771.15 | 529.58 | 511.92 | 714.55 | 3,049.23 | 3,628.94 |
Days of Inventory on Hand |
831.65 | 1,931.42 | 1,646.53 | 1,269.82 | 766.61 | 309.58 | 203.64 | 441.08 | 859.35 | 2,897.54 |
Average Receivables |
1.67 | 1.92 | 2.33 | 2.31 | 3.35 | 3.13 | 1.35 | 0.74 | 0.24 | 0.03 |
Average Payables |
6.99 | 5.13 | 5.39 | 5.37 | 4.84 | 5.06 | 5.38 | 6.38 | 3.94 | 0.55 |
Average Inventory |
9.47 | 9.77 | 8.11 | 5.96 | 3.84 | 2.46 | 2.74 | 2.71 | 1.24 | 0.32 |
Average Assets |
45.87 | 52.09 | 49.11 | 50.36 | 48.05 | 39.63 | 38.73 | 42.34 | 23.60 | 7.98 |
Average Common Equity |
(7.34) | 5.70 | 1.77 | 5.25 | 14.53 | 13.08 | 7.17 | 11.32 | 7.40 | 0.97 |
Columns are period end dates · fundamentals updated 2 Oct 2026